Abstract:BACKGROUND:Kelch-like 6 (KLHL6) is a cancer oncogene previously associated with specific human cancers, such as chronic lymphocytic leukaemia. Here, the mechanisms of KLHL6 function were explored in gastric cancer (GC) cells, in an in vivo experimental tumour model, and the prognostic value of KLHL6 analysis in GC tissue evaluated in a cohort of patients with GC.METHODS:Associations between clinicopathological and survival data and KLHL6 expression in GC tissues were analysed. The effects of downregulation of KLHL6 in GC cells was investigated using proliferation, invasion, apoptosis and lymphangiogenesis assays, and analysis of tumour growth in an in vivo experimental model.RESULTS:KLHL6 was upregulated in 43 per cent of GC tissues compared with 5 per cent of paired non-tumour tissues from 84 patients. KLHL6 protein expression in GC tissues was much higher than that in atrophic gastritis, intestinal metaplasia and dysplasia tissues from benign gastric disease samples. KLHL6 expression was positively related to the intestinal Laurén classification in GC tissues. Downregulated expression of KLHL6 in MGC-803 GC cells reduced colony formation, proliferation, viability, migration and invasion, enhanced apoptosis and inhibited the cell cycle in the G1 phase. Downregulated expression of KLHL6 also suppressed tumour growth in mice. Furthermore, downregulated expression of KLHL6 mRNA reduced the expression of nuclear-associated antigen Ki-67, vascular endothelial growth factor C, hepatocyte growth factor and matrix metalloproteinase 2 in vitro, and KLHL6 protein in tumour tissue of mice.CONCLUSION:Abnormal expression of the KLHL6 oncogene promoted GC progression in vitro and in vivo, and its expression level in tumour tissue was found to be of prognostic value.

Kelch-like Proteins in the Gastrointestinal Tumors

Targeting cyclin-dependent kinases in gastrointestinal cancer therapy.

Targeted Immunotherapies in Gastrointestinal Cancer: From Molecular Mechanisms to Implications

Modulation of gut microbiota in targeted cancer therapy: insights on the EGFR/VEGF/KRAS pathways

PROTACs in gastrointestinal cancers

Targeting kelch-like (KLHL) proteins: Achievements, challenges and perspectives

Prognostic Value of the Cancer Oncogene Kelch-like 6 in Gastric Cancer

Targeting the Wnt/β-catenin Signal Pathway for the Treatment of Gastrointestinal Cancer: Potential for Advancement

Gut Microbiota-Mediated Modulation of Cancer Progression and Therapy Efficacy

Proliferating cell nuclear antigen clamp associated factor, a potential proto-oncogene with increased expression in malignant gastrointestinal tumors

Guarding against digestive-system cancers: Unveiling the role of Chk2 as a potential therapeutic target

Molecular characteristics and immune microenvironment of gastrointestinal stromal tumours: targets for therapeutic strategies

Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications

Protein Kinases as Tumor Biomarkers and Therapeutic Targets

MCM Family in Gastrointestinal Cancer and Other Malignancies: from Functional Characterization to Clinical Implication

Interleukin-1β: Friend or foe for gastrointestinal cancers

Gut microbial metabolites: Shaping future diagnosis and treatment against gastrointestinal cancer

The Role of Fatty Acid Metabolism, the Related Potential Biomarkers, and Targeted Therapeutic Strategies in Gastrointestinal Cancers

Insights into the Role of Glycosyltransferase in the Targeted Treatment of Gastric Cancer

Promising therapeutics of gastrointestinal cancers in clinical trials

The Clinical Significance and Role of CXCL1 Chemokine in Gastrointestinal Cancers